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Abstract: When exceptional situations, such as the COVID-19 pandemic, arise and reliable data is not
available at decision-making times, estimation using mathematical models can provide a reasonable
reckoning for health planning. We present a simplified model (static but with two-time references)
for estimating the cost-effectiveness of the COVID-19 vaccine. A simplified model provides a quick
assessment of the upper bound of cost-effectiveness, as we illustrate with data from Spain, and allows
for easy comparisons between countries. It may also provide useful comparisons among different
vaccines at the marketplace, from the perspective of the buyer. From the analysis of this information,
key epidemiological figures, and costs of the disease for Spain have been estimated, based on mortality.
The fatality rate is robust data that can alternatively be obtained from death registers, funeral homes,
cemeteries, and crematoria. Our model estimates the incremental cost-effectiveness ratio (ICER) to be
5132 € (4926–5276) as of 17 February 2021, based on the following assumptions/inputs: An estimated
cost of 30 euros per dose (plus transport, storing, and administration), two doses per person, efficacy
of 70% and coverage of 70% of the population. Even considering the possibility of some bias, this
simplified model provides confirmation that vaccination against COVID-19 is highly cost-effective.
Keywords: COVID-19 vaccination; mathematical modelling; health economics modelling; Best
Adjustment of Related Values (BARV); Cost-Effectiveness Analysis (CEA); coronavirus; healthcare
expenditures; Quality Adjusted Life Years (QALY); Incremental Cost Effectiveness Ratio (ICER);
collective choice; discount rate
1. Introduction
Since the first publications of efficacy data on COVID-19 vaccines [1,2], a growing
number of other products have been developed in different countries by a number of
pharmaceutical companies. However, it is crucial that a steady and adequate supply is
available to the population within a short period of time. The COVID-19 pandemic has
already imposed significant costs on national economies, causing increasing pressures
on health budgets. Despite the effort it represents, it is essential that sufficient financial
resources are guaranteed to carry out the vaccination plans. In this study, a mathematical
model for cost-effectiveness analysis of COVID-19 vaccination is presented to provide
policymakers with the evidence of the economic value of this health intervention. It is worth
noting that the absence of reliable data, and even more so, data in constant progression,
make this estimation very difficult, especially in the context of a pandemic, when the time
available for producing complex forecasts is limited, and health managers may not have
sophisticated mathematical technology at their disposal. Simple mathematical modeling
could provide an approach and throw some light on this issue [3], and the method and
conclusions of this study can help facilitate setting priorities in the decision-making process
and the allocation of the health care budget.
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In addition to the proposal for the mathematical procedure, this document has three
purposes. Firstly, to present some figures on the impact of COVID-19 on health, in support
of the concept of serious disease, the control of which still requires additional economic
efforts. To this end, the number of quality-adjusted life-years (QALYs) lost to the pandemic
has been calculated; secondly, to establish an estimate of the cost of health care due to
COVID-19 in Spain; and thirdly, to present data on the cost-effectiveness of the vaccine.
2. Materials and Methods
Data for Spain related to the situation of the COVID-19 pandemic on 27 October 2020
and on 17 February 2021 have been calculated using the Best Adjustment of Related Values
(BARV) method, which attempts to adjust reliable figures within a range and calculate other
less reliable but related values by means of an iterative adjustment, so that the possible
errors of all the variables are minimized by minimizing all deviations [4]. Although a
more complex computerized procedure may be used, results may also be obtained using a
simple spreadsheet, with the possibility of adding weighting to more reliable data and by an
iteration process obtaining the results for the less known variables that minimize all errors.
For mortality, the procedure already used in previous work [4] was followed, collecting
the unexpected increase in mortality (excess deaths) registered in four periods from the
Spanish Mortality Database (MoMo) [5], assuming (ceteris paribus) the increase to be due
to COVID-19.
The QALY, Q(xA), representing the number of years (adjusted for quality) for each
group of median age (A) lost as a result of morbidity/mortality due to COVID-19, have
been calculated, based on the estimate of years of life expectancy (LE = x) for age A, using
the formula [6,7]:





Following Attema et al. [8], the utility U for each year obtained from the life table is
discounted for the successive years (constant QALY model). When compared with the stan-
dard discount rate used in business [1/(1 + r)]j−1 this procedure provides similar values.
Each group of current median age A has a life expectancy xA and a yearly variable
Uj utility. Summing over all the discounted remaining years of life (1 to xA) will provide
the adjusted life years lost due to COVID-19. Thus, Uj is the utility ratio for each year
in the rank |A, A + x|; r is a constant discount rate of 3.5%, selected according to the
income of Spain [7,8]. Sensitivity analyses have been done for r = 3% and 4%. Some of
the Uj values, not found in the references, have been computed by linear extrapolation of
neighboring values. Table 1 summarizes the five-year values of the life table used, although
we have computed and used year-by-year values from 50 to 95 years of age, extrapolating
missing data.












0 80.48 0.793623 63.87 85.9 0.79350 68.13
50 31.85 0.687555 21.90 36.8 0.60030 22.10
55 27.42 0.674419 18.49 32.2 0.56993 18.32
60 23.20 0.599138 13.90 27.6 0.53354 14.71
65 19.21 0.589744 11.33 23.1 0.48085 11.10
70 15.43 0.556034 8.58 18.7 0.47353 8.85












75 11.91 0.522736 6.23 14.5 0.46622 6.75
80 8.80 0.489438 4.31 10.6 0.37504 3.99
85 6.25 0.456140 2.85 7.40 0.28387 2.11
90 4.39 0.383721 1.68 5.00 0.11491 0.58
Source: Authors’ computation based on data from Spanish National Institute of Statistics [9] and Eurostat [10].
Data corresponding to 2017. Data of years not included in tables have been calculated by linear extrapolation of
the nearest values.
The table highlights the so-called male-female mortality paradox: Females live longer
but in a worse state of health [11].
To calculate the QALYs lost due to the pandemic in Spain, not only the total num-
ber of deaths has been considered, but also, for those patients discharged from hospital
alive, a weight of morbidity considering their future QALYs (as expected by age and
gender) to be reduced an average of 10% (Qw = 0.9 Q0) forward discharges and 20%
(Qw = 0.8 Q0) for ICU discharges, following weights of a Markov model used for other
chronic diseases [12–14].
Additional data such as population statistics, figures related to influenza, and other
values or ratios used in the text, have been obtained from the corresponding published
institutional statistics [15–18].
3. Results
3.1. Magnitude of the Healthcare Problem: COVID-19 Outbreak Versus Influenza
As of 27 October 2020, the estimated prevalence of COVID-19 in Spain was not very
different from that of AH1N1 influenza, although it must be noted that there was an active
outbreak of the former with about 20,000 new daily notifications at that time (accumulated
incidence of about 500 per 100,000 habitants in 14 days) [16–23]. Table 2 comparatively
presents the information together with Case Fatality Ratio (CFR) and Infectious Fatality
Ratio (IFR) estimations up to that moment.
Table 2. Comparison of COVID-19 and A-Influenza data in Spain as of 27 October 2020.
Population 47,431,688 [1]
COVID-19 ×100,000 ‡ Influenza ×100,000 ‡
Prevalence [2] 7,010,340 14,780 6,521,798 13,750
Confirmed [3] 1,116,738 2354 619,000 1305
Hospitalized 170,789 360 27,657 58
ICU 15,278 32 1800 4
Fatalities 59,422 3900
Mortality (over [1]) 0.13% 125.3 0.01% 8.2
CFR (over [3]) 5.32% 0.63%
IFR (over [2]) 0.85% 0.06%
Source: Authors’ computation with data from sources [20–23]. ICU, intensive care unit. ‡ Inhabitants.
As evidenced by the figures, the prevalence in both cases was about 15%, but COVID-
19 is causing about six times more hospitalizations, over eight times more admissions in
ICU, and fifteen times more fatalities. To facilitate comparison of these data with those in
influenza reports, the alternative method suggested for reporting CFR in ongoing outbreaks
has not been followed [24].
These data for COVID-19 incidence and prevalence in Spain as of that date were not
very different from those in the UK, with about 20,000 new cases per day and over one
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million reported cases, as of 31 October [25]. The data correspond to moments of ongoing
pandemic waves.
Table 3 provides the comparative figures between 27 October and 17 February, and
includes the ratios used in our model based on the number of fatalities (nf).
Table 3. COVID-19 data as of 17 February 2021 compared to data from 27 October 2020.
27 October 2020 17 February 2021 Template
Prevalence [2] 7,010,340 9,814,476 Based on Pub.
Confirmed [3] 1,116,738 3,107,172 Reported
Hospitalized 170,789 306,727 3.45 nf
ICU 15,278 26,477 0.3036 nf
Fatalities (number) 59,422 84,150 nf
Mortality (over [1]) 0.13% 0.18%
CFR (over [3]) 5.32% 2.7%
IFR (over [2]) 0.85% 0.86%
Source: Authors’ computation with data from sources [19–26]. Population 47,431,688 inhabitants.
3.2. COVID-19 Related Expenditures
The «Framework for Estimating Health Spending in Response to COVID-19» re-
port [27]—which includes 214 countries and territories, projecting volumes of people and
costs between 8 March 2020, and 7 March 2021 (52 weeks)—has been published by the
International Monetary Fund and models different scenarios, social distancing, lockdowns,
and other variables. According to its conclusions, «effective social distancing and quaran-
tine reduce the additional health spending from a range of US$0.6–1 trillion globally to
US$ 130–231 billion, and the fatality rate from 1.2 to 0.2 percent, on average» (p. 2). As per
this source, with satisfactory containment of the disease, increase in health expenditures
due to COVID-19 would represent about 0.2–0.3% of the world’s Gross Domestic Product
(GDP) for 2019, «and fatality rate would be 0.1% of the population, on average, across
countries» (p. 8).
The published costs that the disease is generating for healthcare systems, even when
focused only on inpatient and outpatient care, are very variable, representing different
health care approaches. Most of the reports are from the USA, where the healthcare provider
is covered by a combination of payments by companies and users. In the most complicated
cases, hospitalization due to COVID-19 rose to US$75,000 or even more. An average
from US$9764 (for less severe cases) to about US$14,500 per person has been reported
by the Kaiser foundation and other sources [28–31]. According to Avalere, COVID-19
hospitalizations could cost the U.S. healthcare system between US$9.6 billion and $16.9
billion in 2020 [32]. This represents between US$30 and US$50 per inhabitant. Reports
from other countries with lower GDP, such as Mexico or Chile, show lower costs. There
are also systematic reviews on the average length of stay for COVID-19 hospitalizations,
which may be used for cost estimation [33].
Considering the available information and the reported costs for the Spanish Health
Care System [34–38], the direct costs (to 17 February 2020) have been estimated and
summarized in Table 4. Again, this information may not be exhaustive. The expenditure
figure for asymptomatic cases is an estimate that includes over-the-counter medicines. It
is not clear whether all hospitalizations in private centres have been included in these
statistics but considering that most cases are financed by the public system, this uncertainty
has not been very significant.
According to our estimations, an average (cases in ward plus cases in ICU, excluding
outpatient assistance) hospitalization costs about €5900 (US$7139). For Spain (2019), with
a population of 47.3 million and a GDP of €1119,976 M, COVID-19 health care (up to 17
February 2021) will represent about €50 per inhabitant, or around 0.21% of GDP, similar
to the projection for all 2020 already commented on (0.2–0.3%) [27,30]. It must be taken
into consideration that the disease is spreading rapidly, and this value only includes direct
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costs. The average, per day hospitalization cost was estimated at €369 (250–750), for an
average length of stay of 15.9 days, obtained from a large series in France [33,39].
Table 4. Estimation of direct healthcare costs for COVID-19 in Spain as of 17 February 2021 (direct
cost including medication).
HC Provision Number ofCases Cost per Unit
After
Discharge Total
50% of cases with few
symptoms 4,935,398 20 € 98,707,960 €
PC and OP health
assistance 2,639,250 190 € 501,457,500 €
Hospital ward standard 246,236 3700 € 200 € 911,073,200 €
Hospital ward w/comp. 18,534 10,000 € 300 € 185,340,000 €
ICU (including ARDS) 25,548 27,000 € 350 € 689,796,000 €
Total 2,386,374,660 €
Per inhabitant 50 €
Per% of GDP 0.21%
Source: Authors’ computation based on References [26,34–38]. OP, outpatient. PC, primary care. ARDS, acute
respiratory distress syndrome.
The pandemic has brought with it many other economic issues. Some of these are sum-
marized in Table 5, in addition to the direct health care costs mentioned above (points 1–6).
Table 5. Summary of some relevant costs related to COVID-19.
Cost Directly Linked to Health Care
1. Primary care patients with minor symptoms.
2. Primary care for patients later requiring hospitalization or during follow-up after discharge
from hospital.
3. Emergency assistance.
4. Hospitalization and rehospitalization on ward.
5. Use of mechanical ventilation devices.
6. Intensive Care hospitalization and rehospitalization.
7. Special treatments (monoclonal antibodies, convalescent plasma, etc.)
8. Cost related to shrouding, storage, transfer, cremation or burial, and terminal cleaning of
the rooms of the deceased.
9. Operational costs, including staffing related to the increase of activity.
10. Acquisition, training, consumption, and elimination of personal protective equipment for
staff, including orderlies, maintenance personnel, security, cleaning, etc.
11. Cost of the opportunity of delayed assistance to other diseases due to COVID-19.
12. Outpatient drug costs, including pharmacy consultations and over-the-counter treatments.
13. Transport (e.g., ambulances)
14. Prescribed and over-the-counter medication.
General population and business
1. Protective measures, including panels, gloves, hydroalcoholic gels.
2. Related to home lockdown for adults and children, including babysitting for workers with
children remaining locked down at home.
3. Related to labor reduction, readaptation, or loss.
Governmental
1. Reorganization and adaptation of public services, including police, port, and airport
controls, quarantine compliance controls, military emergency services, their protective
equipment, and cleaning agent’s consumption.
2. Relief plans, extra services, and supports for vulnerable people (unemployed, elderly, etc.)
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3.3. Cost-Effectiveness of Vaccination
According to data reported as of 17 February 2021 [26], we have estimated that 554,539
QALYs (539,367–577,679) have been lost either directly due to mortality from COVID-19,
or as a result of future morbidity, without taking into account additional losses, such as the
opportunity costs of delayed treatments for other diseases as a result of the pandemic and
other hidden costs [40]. Table 6 depicts a template for calculating the QALYSs referred to
as the total number of fatalities, a data usually consistent in demographic statistics.
Table 6. Template for calculating COVID-19 adjusted and discounted years (QALYs) resulting from direct mortality and
expected morbidity, based on the total number of fatalities (nf).











Men alive after ICU 0.10242nf 62.6 21.2 12.8 8.6 (8.2–9.0) 1.7 N*Qw
Women alive after ICU 0.11466nf 62.9 22.3 12.7 7.3 (7–7.6) 1.5 N*Qw
Qw = 0.1Q0
Men alive after ward
hospitalization 1.25436nf 66.5 18.3 10.6 7.4 (7.1–7.7) 0.7 N*Qw
Women alive after
ward hospitalization 1.40431nf 68.1 17.8 9.7 6.0 (5.8–6.3) 0.6 N*Qw
Subtotal (morbidity) Σ
Men death by age
(hospital and home) Qw = Q0
<65 0.03702nf 52 30.1 20.2 11.3
(11.2–
11.4) 11.3 N*Qw
65–74 0.06664nf 70 15.5 8.6 6.3 (6.3–6.4) 6.3 N*Qw
>74 0.42459nf 80 12.3 6.4 3.7 (3.6–3.9) 3.7 N*Qw
Women death by age
(hospital and home) Qw = Q0
<65 0.03306nf 55.0 27.1 17.5 9.8 (9.7–9.9) 9.8 N*Qw
65–74 0.05951nf 70.0 15.5 8.6 5.6 (5.5–5.8) 5.6 N*Qw
>74 0.37918nf 80.0 12.3 6.4 3.7 (3.6–3.9) 3.7 N*Qw
Subtotal (mortality) Σ
Source: Authors’ computation with data from sources [12,13,26,41–43]. Discount rate (3%, 3.5%, 4%).
The question of age and morbi-mortality for COVID-19 will give rise to issues, such as
whether the patients that have died with the disease represent a subset of ill persons with
less QALY than the average for the age, or for which population it would be more cost-
effective to program early vaccinations [44]. At an estimated cost of €30 per shot (vaccine
plus transport, storing, and administration) [45,46], the following table (Table 7) offers
the cost-effectiveness analysis for different percentages of vaccine efficacy and discount
rates (r = 3%, 3.5%, 4%), and different percentages of the population included in a vaccine
program of two shots.
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the incre-
mental cost resulting from vaccination by the measure of health outcome (incremental
effect in QALYs) to provide a ratio of ‘extra cost per extra unit of health effect’ [47]. ICERs
may be compared across disease areas and are evaluated with a pre-determined cost-
effectiveness threshold.
Vaccination of about 70% of the Spanish population, with a conservative 70% ratio of
efficacy and two shots, will result in €5132 (4926–5276) per QALY gained.
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Table 7. Incremental cost-effectiveness ratio (ICER) for COVID-19 vaccine adjusted by different




Efficacy 50 60 70 80 90
Overall QALY
(r = 3%) 539,367 10,553 8794 7538 6595 5863
Overall QALY
(r = 3.5%) 554,539 10,264 8553 7331 6415 5702
Overall QALY




Efficacy 50 60 70 80 90
Overall QALY
(r = 3%) 539,367 8442 7035 6030 5276 4690
Overall QALY
(r = 3.5%) 554,539 8211 6843 5865 5132 4562
Overall QALY




Efficacy 50 60 70 80 90
Overall QALY
(r = 3%) 539,367 7387 6156 5276 4617 4104
Overall QALY
(r = 3.5%) 554,539 7185 5987 5132 4491 3992
Overall QALY
(r = 4%) 577,679 6897 5748 4926 4311 3832
Source. Authors’ calculation. Cost per two shots, vaccine plus inoculation (30 € each).
For comparison, the cost-effectiveness threshold, or basal-case ICER, was set between
€22–33,000. NICE (National Institute for Health and Care Excellence) aims to spend less
than £25,000 (€27,500) per QALY. A similar value (CAN$40,000 = €27,200) was set for other
vaccination program by Brisson et al. [48].
It must be considered that the ICER threshold depends on a willingness to pay, and in
consequence, on GDP. The World Health Organization suggests referring cost-effectiveness
to GDP [49]. Although US$50,000 has been considered for a long time in the USA as
the limit for the cost-effective threshold, this value has been criticized as being low [50].
The US threshold (2017 data) for very cost-effective (considered as less than one times
GDP) has been reported to be <US$59,532; for cost-effective (between 1–3 times GDP)
<= US$178,596; and considered not to be cost-effective (greater than three times GDP) when
>US$178,596 [51]. Neumann et al. [50] suggest as a rule US$50, 100, and 200 thousand, for
each range, matching very roughly with less than one times GDP per capita, between one-
and three-times GDP, and over three times GDP. In any case, the prediction of our model
for COVID-19 vaccine cost-effectiveness is well under the threshold; the vaccine is highly
cost-effective [52,53]. Table 8 overviews the ICER of some vaccination reports in the last
two decades:
The numerator of the cost/quality ratio (i.e., the cost of vaccination in Spain) is not
expected to increase, as the cost per dose may even be reduced by competition between
vaccines, and the Spanish population will not experience appreciable changes in the short
term. However, the denominator (years lost) continues to grow with a significant number
of new deaths each day, so the ICER will progressively decrease as the pandemic continues
to spread.
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Table 8. Incremental cost-effectiveness ratio (ICER) of some vaccination plans reported in the literature for the last two decades with conversion to EUR at the corresponding date
for the year.
Vaccination Target Population ICER Currency Rate (1€→) ICER (€) d/Rate Article Year First Author
Pneumoco Adults 65 and over 11–33,000 € 11–33,000 0–5% Bibliometric 2000 Ament
Lyme disease Resident endemic areas 62,300 $US (2001 = 0.89) 70,000 3% Modeling 2001 Shadick
Influenza Adults 50–64 y/o 10,766 £ (2005 = 0.67) 16,069 NA Modeling 2005 Turner
Influenza Children 6 m–4 y/o <25,000 $US (2006 = 1.25) ≤19,925 NA Modeling 2006 Prosser
H Papilloma (HPV) 12–24 y/o females 3000 $US (2007 = 1.37) 2190 3% Modeling 2007 Insinga
Papilloma (HPV) 12–24 y/o females+ males 16,000 $US (2007 = 1.37) 11,679 3% Modeling 2007 Insinga
H Papilloma (HPV) 12 y/o females 21–31,000 $CAN (2007 = 1.46) 30,666–45,260 3% Modeling 2007 Brison
A Hepatitis Travellers 26,046 $US (2008 = 1.46) 17,840 5% Bibliometric 2008 Anonychuk
A Hepatitis Health care workers 129,046 $US (2008 =1.46) 88,388 NA Bibliometric 2008 Anonychuk
A Hepatitis Military 16,332 $US (2008 = 1.46) 11,186 NA Bibliometric 2008 Anonychuk
A + B Hepatitis Children <35,000 $US (2008 =1.46) <23,972 NA Bibliometric 2008 Anonychuk
H Papilloma (HPV) NA 32,884 € 32,884 NA Modeling 2008 Bergeron
Herpres Zoster Adults 60 and over 20,400 £ (2009 = 0.89) 22,921 6% Modeling 2009 Van Hoek
pH1N1 Influenza 6 m–64 y/o 8000–52,000 $US (2009 = 1.39) 5755–37,410 3% Modeling 2009 Prosser
Rotavirus Children < 5 y/o 23,298 £ (2009 = 0.89) 26,178 3.5% Modeling 2009 Martin
Rotavirus Children < 5 y/o 61,000 £ (2009 = 0.89) 68,539 3.5–3% Modeling 2009 Jit
H1N1v Influenza Age groups 2733–3215 £ (2010 = 0.86) 2733–3215 3.5% Modeling 2010 Baguelin
H Papilloma (HPV) 12 y/o females 1917 € 1917 3% Modeling 2010 Olsen
H Papilloma (HPV) Girls 12 y/o 3583 € 3583 3–5% Modeling 2015 Olsen
Influenza (IIV3) Adults 65 and over 3690 $US (2016 = 1.11) 3324 3% Modeling 2016 Raviotta
Influenza (TIV) Adults 65 and over 10,750 € 10,750 0% Modeling 2018 Capri
Source: Authors’ compilation.
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In other words, for every day of active illness, there will be a reduction in the ICER, as
this represents a continuous increase in the loss of QALYs (denominator). However, if the
number of patients alive after contracting COVID-19 (and consequently having immunity,
assuming this lasts a reasonable time) increases substantially, it would also impact on
reducing the cost-effectiveness of the vaccine.
In addition, vaccination will generate savings in health expenses and alleviate the
economic consequences of the pandemic in both the health insurance sector and private
hospital centres, which, as a result of COVID-19, are currently suffering wage cuts, lay-offs,
and risk of financial unfeasibility [54]. This is just one of the economic issues related to
COVID-19.
4. Discussion
In situations of uncertainty, when reliable data are either not available or arrive
late, or the pressure on care is so great that statistics cannot be relied upon, the use of
simple mathematical estimation models can provide information reliable enough for health
planning, since in this case a highly accurate numerical assessment is not required, but
rather a range. The consideration of COVID-19 as a serious issue must be easily deduced,
not only from the data in tables above, but also from the social and political movements and
urgent plans for action issued by national and international authorities, EU included [55].
The data in this paper refer to a disease with morbidity and mortality in progression,
but what is important is that the model allows easy recalculation with the updating
of information.
The procedure followed, including how CFR and IFR were computed, may have
some limitations: Firstly, the method may estimate data that could not be fully accurate.
Secondly, it is better to compute CFR during an active outbreak by the ratio death/(death +
recovered) [56]. However, they have been considered as one-day ‘snapshots’ analyses and
carried out, in the case of October values, homogeneously with data related to influence
for easy comparisons. The importance and impact of our approach are further emphasized
by the constant interest in the costs of the pandemic by the media [57], with estimations
of values not far from our own results. Although, considering a relatively wide range for
imprecision, the values serve as a proxy for the severity of the pandemic as compared to
influenza and the economic benefits of vaccination.
A further constraint comes from the fact that economic evaluations of infectious
disease interventions are often based on predictions from systems of ordinary differen-
tial equations (ODEs) or Markov models, either static or, more typically, dynamic ones
that consider herd immunity, which is crucial to avoid overestimation of infection preva-
lence [58–60], although other approaches are possible [61]. Our simplified model may be
criticized for not following that trend. However, studies of herd immunity on COVID-19
are already available [62], with seroprevalence rates very low (about 5%). There is also the
issue of changing age, as the dynamic model could predict an increase in the average age
at infection after immunization, which could impact the estimate of the cost-effectiveness
of the program, particularly in this case of serious disease as a function of age. According
to our model, about 80% of fatalities already correspond to subjects aged over 74. A multi-
national meta-analysis, with a total of 611,583 subjects, showed that 82.9% of the fatalities
were for those 70 and over, very close to our model considering the four years (70–74)
range difference and regional variations [63]. The fourth series of mortality data from
MoMo [5] do not show significant changes in mortality ratios among waves by age, but it
is true that the vaccination effect is not included, as the number of cases vaccinated up to
17 February that could be included in the mortality figure is to be considered nearly zero.
Additionally, this limitation may result in less relevant, considering that constant models
tend to underestimate the cost-effectiveness of the immunization program [59]. This papers
presents a simplified mathematical model to establish a range for the cost-effectiveness
of COVID-19 vaccination, rather than the procurement of a totally accurate computation,
Mathematics 2021, 9, 566 10 of 15
which in any case does not seem essential as long as the values obtained are well below the
cost-effectiveness threshold.
If SARS-CoV-2 behaves as A(H1N1) influenza with periodic outbreaks—something
not improbable as both are RNA viruses—even with measures of social distancing and
periodic lockdowns (each time less popular among citizens), Spain should expect, in the
next 10 years, between 7 and 12 million of confirmed cases, and over 400,000 deaths
(at decreasing ratio of about 45,000 per year), a value consistent with estimations in the
UK by Sandmann et al. [64]. Following this reference—assuming 75% efficacy, 10 years
protection and 10% of revaccination, discount rate of 3.5% and monetized health impact
at £20,000 (€22,000)—vaccination (plus physical distancing) versus no vaccination will
represent between €6.11 and €21.95 million economic gain or Net Monetary Benefit (NMB)
per million population (i.e., €288.9–€1038.5 million for Spain in ten years) [64]. Values are
consistent after sensitivity analyses and the proportion of mortality in the UK. Simulations
studies advocate efficacies of at least 60% [65]. This brings up the issue of the unknown
duration of immunoprotection. If a periodic COVID-19 vaccination schedule were to be
established, i.e., a schedule similar to that for other viral processes, such as influenza, the
cost-effectiveness of vaccination could change appreciably.
The method of cost-effectiveness has been chosen because among the main indicators
used in the economic analysis of healthcare planning, (cost-benefit, cost-effectiveness, and
cost-utility), the effectiveness perspective is useful for decision-making on how best to
allocate resources, while the cost-benefit ratio analysis helps decision-making on overall
resource allocation. Quality-adjusted life year analysis allows direct comparison of a wide
range of health interventions [66,67]. For QALYs, the use of utility scores from a life table
(Table 1) eases the calculation of the adjusted number of years lost for the average age in
each of the groups studied. The median age of about 70 for patients admitted in Spanish
hospitals for COVID-19 [21] is not far from data from another report, also from a country
with a National Health System, reviewing 16,749 cases [68].
Additional reduction for chronicity, mainly resulting from permanent inflammatory
handicaps (e.g., pulmonary fibrosis) requiring extra healthcare resources, has been consid-
ered in survivors in an average of 10% [Qw = 0.9 Q0] in cases of ward discharges, and 20%
[Qw = 0.8 Q0] after ICU discharge. Similar utility scores have been obtained with Markov
model methodology in cases of other chronic diseases (e.g., in Diabetes Mellitus, a disease
that also requires periodic visits and controls) [69,70]. Sensitivity analyses of this utility
score at ±10% (i.e., 0.09–0.11, and 0.18–0.22, respectively) maintain significant QALY gains
in all cases; Qw could be additionally adjusted for protection length of time and annual
revaccination rate. A weighted variation related to age could also be considered.
Except for some promising drugs currently in development, there is no effective
treatment for COVID-19. The first option considered was to examine the role that herd
immunity might have. We have already predicted that herd immunity would not play a
major role as a barrier to COVID-19 [4], as confirmed by subsequent serological studies [71].
Moreover, data suggest transmission, even from asymptomatic patients, in many cases [72].
With the results of over 365,000 tests done in England showing that antibody response
to SAR-CoV-2 wanes over time [73], and reinfection cases reported [74], the possibility of
herd immunity as a barrier remains low, although it must be admitted that the expected
severity of reinfected cases should, at least theoretically, be lower, due to the residual mem-
ory effect of the immune system, which is characteristic of infections [75–77]. Therefore,
at present, there is only one rational, proactive measure to increase herd immunity and
effectively reduce the number of cases of COVID-19, that being vaccination plans [78].
A cost of the vaccine of about £10 for the product, with another £10 for administra-
tion, as estimated by Sandmann et al. [64], which seems reasonable for a country with a
National Health System. According to a governmental report in Spain, each dose for the
vaccine of influenza costs the Spanish Health Care System an average of €4.3, and the shot
about €6.0 [79].
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Considering not only the cost of extra protection measures and time required for
isolation of health professionals prior to COVID-19 vaccine administration, and the high
demand for a new product, but also the massive acquisitions already announced—it
must be remembered that the EU has made arrangement for buying 300 million doses
of the Sanofi-GSK vaccine—a range between 20–30 Euros for each shot (vaccine plus
administration) when bought at great volume seems reasonable [45,80–82].
According to Reuters, there is a plan to inoculate about 50 million US citizens for
about US$40 per person (€34.5) [83]. Other elements that could influence price are the
low-temperature condition for transport and storage, particularly in developing countries,
where the role of interventions may differ [84–86]; the forecast of scenarios may change in
each case [87]. It should be noted that our study refers to two doses of vaccine, but there is
no evidence to indicate that COVID-19 will not require revaccination, even for life. A plan
in this case, like that of influenza, will represent about 10 times the cost indicated [79].
Finally, there may also be factors not captured in the QALY formulas, including
indirect costs, the value of returning to normal life, the effects on mental health (anxiety,
depression, fears of losing jobs, and lockdown, production losses, etc., that will additionally
increase the benefits of vaccination. In other words, that cost-effectiveness measured with
the standard procedures may not be the only thing that matters [88,89].
5. Conclusions
Left alone, successive COVID-19 outbreaks could represent between 7 and 12 million
confirmed cases and over 400,000 deaths in Spain in 10 years. Vaccination against SARS-
CoV-2 is the only reasonable approach, and seems clearly indicated after analysis of the
risks of getting vaccinated versus not getting vaccinated, together with the vaccine data
available [1,2].
The cost estimates with our mathematical model are simple, easily reproducible, and
fit well with other available data. Data of Table 6 may be used for other purposes, e.g., in
case of shortage of vaccines, to compare different commercial products.
Data allows us to appraise an ICER of 5132 euros (4926–5276 euros)—even while using
a conservative approach of vaccinating about 70% of the Spanish population with a vaccine
efficacy of about 70% (two injections). This is a very cost-effective ratio as a result of a
vaccination plan; furthermore, the ratio improves (i.e., the cost decreases) for each day of
new cases reported after 17 February 2021.
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